{
    "doi": "https://doi.org/10.1182/blood.V126.23.1581.1581",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=3234",
    "start_url_page_num": 3234,
    "is_scraped": "1",
    "article_title": "Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA ",
    "article_date": "December 3, 2015",
    "session_type": "632. Chronic Myeloid Leukemia: Therapy: Poster I",
    "topics": [
        "adenocarcinoma",
        "alcohol abuse",
        "american college of apothecaries",
        "anterior cerebral artery",
        "antibodies, anticardiolipin",
        "blast cells",
        "chromosome abnormality",
        "drug administration routes",
        "patient protection and affordable care act",
        "hematopoietic stem cell transplantation"
    ],
    "author_names": [
        "Christian T. Dietz, PhD",
        "Alice Charlotte Fabarius, PhD",
        "Michael Lauseker, PhD",
        "Susanne Saussele",
        "Lida Kalmanti",
        "S\u00e9bastien Rinaldetti",
        "Claudia Haferlach, MD",
        "Brigitte Schlegelberger, MD PhD",
        "Martine Jotterand",
        "Alois Gratwohl",
        "Axel R. Zander, Professor",
        "Nicolaus Kr\u00f6ger",
        "Dietrich W. Beelen, MD",
        "J\u00fcrgen Novotny",
        "Christoph Nerl",
        "Christof Scheid, MD PhD",
        "Karsten Spiekermann",
        "Jiri Mayer, MD",
        "Herbert G. Sayer",
        "Christiane Falge",
        "Donald Bunjes, MD",
        "Hartmut D\u00f6hner, Prof. Dr.",
        "Arnold Ganser",
        "Peter Brossart, MD",
        "Rainer Schwerdtfeger",
        "Herrad Baumann",
        "Rolf Kuse",
        "Hans Walter Lindemann, MD",
        "Matthias Bormann",
        "Bernd Hertenstein, MD",
        "Gabriela M. Baerlocher",
        "Carlo Aul, MD",
        "Peter Staib",
        "Matthias Edinger, MD",
        "Michael Schatz",
        "Axel A Fauser",
        "Renate Arnold, MD",
        "Dieter K. Hossfeld, MD",
        "Hans-Jochem Kolb",
        "Susanne Schnittger, PhD",
        "Martin C. M\u00fcller, MD",
        "Andreas Reiter, MD",
        "Andreas Hochhaus, MD",
        "Markus Pfirrmann",
        "Joerg Hasford",
        "Michele Baccarani",
        "Ruediger Hehlmann, MD"
    ],
    "author_affiliations": [
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "Institut f\u00fcr medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "MLL M\u00fcnchner Leuk\u00e4mielabor, M\u00fcnchen, Germany "
        ],
        [
            "Institut f\u00fcr Humangenetik, Medizinische Hochschule, Hannover, Germany "
        ],
        [
            "Service de g\u00e9n\u00e9tique m\u00e9dicale, Centre Hospitalier Universitaire Vaudois (CHUV),, Lausanne, Switzerland "
        ],
        [
            "Behandlungszentrum Stammzelltransplantation, Universit\u00e4tsspital, Basel, Switzerland "
        ],
        [
            "Interdisziplin\u00e4re Klinik und Poliklinik f\u00fcr Stammzelltransplantation, Universit\u00e4tsklinikum Eppendorf, Hamburg, Germany "
        ],
        [
            "Interdisziplin\u00e4re Klinik und Poliklinik f\u00fcr Stammzelltransplantation, Universit\u00e4tsklinikum Eppendorf, Hamburg, Germany "
        ],
        [
            "Klinik f\u00fcr Knochenmarktransplantation, Universit\u00e4stsklinikum, Essen, Germany "
        ],
        [
            "Klinik f\u00fcr H\u00e4matologie, Universit\u00e4tsklinikum, Essen, Germany "
        ],
        [
            "Klinik f\u00fcr H\u00e4matologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin, Klinikum Schwabing, M\u00fcnchen, Germany "
        ],
        [
            "Klinik I f\u00fcr Innere Medizin, Universit\u00e4tsklinikum, K\u00f6ln, Germany "
        ],
        [
            "Medizinische Klinik und Poliklinik III, Klinikum der Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany "
        ],
        [
            "Intern\u00ed hematologick\u00e1 a onkologick\u00e1 klinika, Masarykova univerzita, Brno, Czech Republic "
        ],
        [
            "Klinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum, Jena, Germany "
        ],
        [
            "Medizinische Klinik 5, Klinikum N\u00fcrnberg-Nord, N\u00fcrnberg, Germany "
        ],
        [
            "Department of Internal Medicine III, University of Ulm, Ulm, Germany "
        ],
        [
            "Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum, Ulm, Germany "
        ],
        [
            "Klinik f\u00fcr H\u00e4matologie, H\u00e4mostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule, Hannover, Germany "
        ],
        [
            "Medizinische Klinik III f\u00fcr H\u00e4matologie und Onkologie, Universit\u00e4tsklinikum, Bonn, Germany "
        ],
        [
            "KMT-Zentrum, Deutsche Klinik f\u00fcr Diagnostik, Wiesbaden, Germany "
        ],
        [
            "KMT-Zentrum, Deutsche Klinik f\u00fcr Diagnostik, Wiesbaden, Germany "
        ],
        [
            "Abteilung f\u00fcr H\u00e4matologie und Stammzelltransplantation, Asklepios Klinik St. Georg, Hamburg, Germany "
        ],
        [
            "Klinik f\u00fcr H\u00e4matologie und Onkologie, St.-Marien-Hospital, Hagen, Germany "
        ],
        [
            "I. Medizinische Klinik, Klinikum Bremen-Mitte, Bremen, Germany "
        ],
        [
            "I. Medizinische Klinik, Klinikum Bremen-Mitte, Bremen, Germany "
        ],
        [
            "Universit\u00e4tsklinik f\u00fcr H\u00e4matologie und h\u00e4matologisches Zentrallabor, Inselspital, Bern, Switzerland "
        ],
        [
            "Klinik f\u00fcr Onkologie und H\u00e4matologie, HELIOS St. Johannes Klinik, Duisburg, Germany "
        ],
        [
            "Klinik f\u00fcr H\u00e4matologie und Onkologie, St. Antonius Hospital, Eschweiler, Germany "
        ],
        [
            "Abteilung H\u00e4matologie und Internistische Onkologie, Universit\u00e4tsklinikum, Regensburg, Germany "
        ],
        [
            "II. Medizinische Klinik, St. Vincentius Kliniken, Karlsruhe, Germany "
        ],
        [
            "Klinik f\u00fcr Knochenmarktransplantation und H\u00e4matologie/Onkologie, Idar-Oberstein, Germany "
        ],
        [
            "Medizinische Klinik mit Schwerpunkt H\u00e4matologie, Onkologie und Tumorimmunologie, Campus Virchow-Klinikum, Charit\u00e9 - Universit\u00e4tsmedizin, Berlin, Germany "
        ],
        [
            "II. Medizinische Klinik, Universit\u00e4tsklinikum Eppendorf, Hamburg, Germany "
        ],
        [
            "Medizinische Klinik und Poliklinik III, Klinikum der Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany "
        ],
        [
            "MLL M\u00fcnchner Leuk\u00e4mielabor, M\u00fcnchen, Germany "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "Universit\u00e4tsklinikum Jena, Jena, Germany "
        ],
        [
            "Institut f\u00fcr medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany "
        ],
        [
            "Institut f\u00fcr medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany "
        ],
        [
            "Istituto di Ematologia, Universita di, Bologna, Italy"
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ]
    ],
    "first_author_latitude": "49.4924375",
    "first_author_longitude": "8.486733399999999",
    "abstract_text": "During the course of chronic myeloid leukemia (CML) progression to blast crisis (BC) is thought to be caused by genetic instability such as cytogenetic aberrations in addition to the translocation t(9;22)(q34;q11). We have shown previously that major route ACA indicate an unfavorable outcome (Fabarius et al., Blood 2011). We now investigate whether there is a correlation in time between appearance of major route ACA and increase in blast count. Methods: Cytogenetic data and blast count in the peripheral blood were available from 1,290 CML patients recruited to the German CML-studies III (621 patients) and IIIa (669 patients) from January 1995 to January 2004. Treatments were interferon-alpha-based or related allogeneic stem cell transplantation (HSCT). Presence of ACA and major route ACA was considered as a time-dependent covariate. Multivariate proportional hazards models were estimated taking Euro CML score, study III vs. IIIa and stem cell transplantability into account. Cumulative incidences of blast increases were calculated starting at the date of the first ACA or major route ACA, respectively, regarding death as a competing risk. Patients were censored at the date of HSCT with an unrelated donor. Results: 1,287 patients were evaluable with median observation times of 13 and 12 years and a 10-year survival of 48% and 61% in CML studies III and IIIa, respectively. 258 patients progressed to BC with a cumulative 10-year incidence of 20%. 195 patients displayed ACA during the course of disease. 45 patients (15.7%) showed ACA already at diagnosis. 44 patients showed unbalanced minor route, 29 balanced minor route aberrations, 23 -Y. 109 patients showed major route aberrations including 10 with other prior ACA. In a multivariate analysis on 1,257 patients, patients with ACA had a hazard ratio (HR) for a blast increase of between 2.0-2.2 (p<0.001) for blast increases to \u22651%, \u22655%, \u226510%, \u226515%, \u2265 20% and \u226530% compared with patients without ACA (Table). When the same model was performed for major route ACA only at any time during disease, HRs of 2.2-2.7 (p<0.001) were found. For ACA without major route ACA HRs were 1.6-2.1 (p<0.001). In the multivariate analyses of major route ACA vs. no major route ACA a blast increase of 1-5% after diagnosis of major route ACA seems already indicative of progression. 5 years after the diagnosis of any ACA the cumulative incidence for a blast increase was 30% (95%- confidence interval (CI): 23-38%), of a major route ACA 40% (95%- CI: 28-49%). The 6-year probability of death without blast increase was 10%. 14 additional patients received an unrelated transplant of which 6 died. We conclude that ACA, particularly major route ACA, precede an increase of blasts. Major route ACA have to be considered as a prognostic indicator for disease progression at any time. Table 1.  Blast increase to . HR (univariate): ACA vs. no ACA . HR(multivariate)*: ACA vs. no ACA . HR (univariate): major route ACA vs. no major route ACA . HR (multivariate)*: major route ACA vs. no major route ACA . \u226530% 2.409 2.139 2.646 2.203 \u226520% 2.413 2.144 2.656 2.211 \u226515% 2.415 2.161 2.868 2.426 \u226510% 2.416 2.160 2.799 2.357 \u22655% 2.286 2.047 2.719 2.278 \u22651% 2.209 1.999 3.171 2.684 Blast increase to . HR (univariate): ACA vs. no ACA . HR(multivariate)*: ACA vs. no ACA . HR (univariate): major route ACA vs. no major route ACA . HR (multivariate)*: major route ACA vs. no major route ACA . \u226530% 2.409 2.139 2.646 2.203 \u226520% 2.413 2.144 2.656 2.211 \u226515% 2.415 2.161 2.868 2.426 \u226510% 2.416 2.160 2.799 2.357 \u22655% 2.286 2.047 2.719 2.278 \u22651% 2.209 1.999 3.171 2.684 View Large *adjusted to Euro-Score, study (III vs. IIIa) and transplantability Disclosures Saussele: ARIAD: Honoraria; BMS: Honoraria, Other: Travel grant, Research Funding; Pfizer: Honoraria, Other: Travel grant; Novartis Pharma: Honoraria, Other: Travel grant, Research Funding. Haferlach: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Scheid: Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Baerlocher: Geron Corporation: Research Funding; Novartis: Research Funding. Schnittger: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. M\u00fcller: BMS: Consultancy, Honoraria, Research Funding; Ariad: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Hochhaus: ARIAD: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Pfirrmann: BMS: Consultancy, Honoraria; Novartis Pharma: Consultancy, Honoraria. Baccarani: Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; NOVARTIS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ARIAD Pharmaceuticals, Inc.: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Hehlmann: BMS: Consultancy; Novartis Pharma: Research Funding."
}